Friday, July 6, 2018

NEW YORK (Reuters) - In the escalating battle over U.S. prescription drug prices, major pharmaceutical companies are scrambling to limit the economic damage from a new U.S. insurer tactic that coaxes patients away from expensive drugs.


from Reuters: Health News https://ift.tt/2KwyLgF

Related Posts:

  • LATEST HEALTH NEWSMore than 34,000 people across Europe caught measles in the first two months of 2019, with the vast majority of cases in Ukraine, the World Health Organization said on Tuesday as it urged authorities to ensure vulnerable peop… Read More
  • LATEST HEALTH NEWSGV, Alphabet Inc's venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases. from Reuters: Health … Read More
  • LATEST HEALTH NEWSJohnson & Johnson agreed to pay about $1 billion to resolve the bulk of lawsuits claiming the company sold defective metal-on-metal hip implants that ultimately had to be removed, Bloomberg reported on Tuesday, citing peo… Read More
  • LATEST HEALTH NEWSJacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. from Reuters: Health News https://reut.rs/2H4HlzL … Read More
  • LATEST HEALTH NEWSThree out of four Americans believe children should be vaccinated against measles even if their parents object, a Reuters/Ipsos poll found, showing little sympathy for the anti-vaccination movement that U.S. officials blame f… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner